This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy MannKind Corporation stock | $2.95

Own MannKind Corporation stock in just a few minutes.

Posted

Fact checked

MannKind Corporation is a biotechnology business based in the US. MannKind Corporation shares (MNKD) are listed on the NASDAQ and all prices are listed in US Dollars. MannKind Corporation employs 232 staff and has a trailing 12-month revenue of around USD$62.7 million.

How to buy shares in MannKind Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for MannKind Corporation. Find the stock by name or ticker symbol: MNKD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until MannKind Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.95, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of MannKind Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of MannKind Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

MannKind Corporation share price

Use our graph to track the performance of MNKD stocks over time.

MannKind Corporation shares at a glance

Information last updated 2020-12-01.
Latest market close USD$2.95
52-week range USD$0.8 - USD$3.2
50-day moving average USD$2.3562
200-day moving average USD$1.8507
Wall St. target price USD$3.1
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.354

Buy MannKind Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy MannKind Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

MannKind Corporation price performance over time

Historical closes compared with the close of $2.95 from 2020-12-04

1 week (2020-11-25) 2.95
1 month (2020-11-06) 29.39%
3 months (2020-09-04) 79.88%
6 months (2020-06-05) 110.71%
1 year (2019-12-05) 147.90%
2 years (2018-12-04) 70.52%
3 years (2017-12-05) -1.99%
5 years (2015-12-04) 52.85%

MannKind Corporation financials

Revenue TTM USD$62.7 million
Gross profit TTM USD$35.1 million
Return on assets TTM -17.72%
Return on equity TTM 0%
Profit margin -71.92%
Book value $-1.035
Market capitalisation USD$693.2 million

TTM: trailing 12 months

Shorting MannKind Corporation shares

There are currently 21.7 million MannKind Corporation shares held short by investors – that's known as MannKind Corporation's "short interest". This figure is 14.6% down from 25.4 million last month.

There are a few different ways that this level of interest in shorting MannKind Corporation shares can be evaluated.

MannKind Corporation's "short interest ratio" (SIR)

MannKind Corporation's "short interest ratio" (SIR) is the quantity of MannKind Corporation shares currently shorted divided by the average quantity of MannKind Corporation shares traded daily (recently around 3.2 million). MannKind Corporation's SIR currently stands at 6.78. In other words for every 100,000 MannKind Corporation shares traded daily on the market, roughly 6780 shares are currently held short.

However MannKind Corporation's short interest can also be evaluated against the total number of MannKind Corporation shares, or, against the total number of tradable MannKind Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MannKind Corporation's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 MannKind Corporation shares in existence, roughly 90 shares are currently held short) or 0.094% of the tradable shares (for every 100,000 tradable MannKind Corporation shares, roughly 94 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against MannKind Corporation.

Find out more about how you can short MannKind Corporation stock.

MannKind Corporation share dividends

We're not expecting MannKind Corporation to pay a dividend over the next 12 months.

Have MannKind Corporation's shares ever split?

MannKind Corporation's shares were split on a 1:5 basis on 3 March 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MannKind Corporation shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for MannKind Corporation shares which in turn could have impacted MannKind Corporation's share price.

MannKind Corporation share price volatility

Over the last 12 months, MannKind Corporation's shares have ranged in value from as little as $0.8 up to $3.2. A popular way to gauge a stock's volatility is its "beta".

MNKD.US volatility(beta: 2.1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MannKind Corporation's is 2.1048. This would suggest that MannKind Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

MannKind Corporation overview

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site